The HCCR oncoprotein as a biomarker for human breast cancer

Clinical Cancer Research

Volumn 11, Issue 21, 2005, Pages 7700-7708

  Jung, Sang Seol ^a   Park, Hyung Soon ^c   Lee, Insong James ^d   Namkoong, Hong ^a   Shin, Seung Min ^a   Cho, Goang Won ^a   Ha, Seon Ah ^a   Park, Yong Gyu ^a   Lee, Youn Soo ^a   Ko, Jesang ^b   Kim, Jin Woo ^a  

^a The Catholic University of Korea   (South Korea)

^b Korea University   (South Korea)

^c KeyGene Life Science Institute   (South Korea)

^d UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BIOLOGICAL MARKER; CA 15-3 ANTIGEN; EPITOPE; GLUTAMYLGLUTAMYLTHREONYLASPARTYLPHENYLALANYLLEUCYLASPARTYLISOLEUCYLTYROSYLH ISTIDYLALANYLPHENYLALANYLARGININE; HCCR ONCOPROTEIN; HISTIDYLPHENYLALANYLTRYPTOPHYLTHREONYLPROLYLLYSINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BCS 1; ONCOPROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER STAGING; CARCINOGENESIS; CELL SELECTION; CELL SURFACE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SEROLOGY; VALIDATION PROCESS; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; ANTIBODIES; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CELL LINE; CELL LINE, TUMOR; CELL SEPARATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EPITOPES; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MICROSCOPY, CONFOCAL; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM METASTASIS; ONCOGENE PROTEINS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TRYPSIN; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 27744516965     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2609     Document Type: Article

References (32)

1. Howe HL, Wingo PA, Thun MJ, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001;93:824-42.
2. Baselga J, Norton L. Focus on breast cancer. Cancer cell 2002;1:319-22.
3. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 2000;355:1822.
4. Lamerz R, Stieber P, Fateh-Moghadam A. Serum marker combinations in human breast cancer [review]. In Vivo (Athens, Greece) 1993;7:607-14.
5. American Society of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996;14:2843-77.
6. Bast RC, Jr., Ravdin P, Hayes DF, et al. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-78.
7. Ko J, Lee YH, Hwang SY, et al. Identification and differential expression of novel human cervical cancer oncogene HCCR-2 in human cancers and its involvement in p53 stabilization. Oncogene 2003;22:4679-89.
8. Yoon SK, Lim NK, Ha SA, et al. The human cervical cancer oncogene protein is a biomarker for human hepatocellular carcinoma. Cancer Res 2004;64:5434-41.
9. Ko J, Shin SM, Oh YM, et al. Transgenic mouse model for breast cancer: induction of breast cancer in novel oncogene HCCR-2 transgenic mice. Oncogene 2004;23:1950-3.
10. 2-M of ErbB2-positive breast cancer cells. Cell Growth Differ 1999;10:61-71.
11. Ballangrud AM, Yang WH, Palm S, et al. α-Particle emitting atomic generator (actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clin Cancer Res 2004;10:4489-97.
12. Menendez JA, Lupu R, Colomer R. Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER-2/neu-overexpressing human breast cancer cells to docetaxel (taxotere). Breast Cancer Res Treat 2004;84:183-95.
13. Ostrakhovitch EA, Cherian MG. Role of p53 and reactive oxygen species in apoptotic response to copper and zinc in epithelial breast cancer cells. Apoptosis 2005;10:111-21.
14. Brodowicz T, Kandioler D, Tomek S. et al. Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status. Br J Cancer 2001;85:1764-70.
15. Munoz-Gamez JA, Martin-Oliva D, Aguilar-Quesada R, et al. PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis. Biochem J 2005;386:119-25.
16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)). Methods 2001;25:402-8.
17. Kennett RH. Cell fusion. Methods Enzymol 1979;58:345-59.
18. Armandola EA, Mariani SM, Ferrone S. Serological and molecular characterization of mouse anti-idiotypic monoclonal antibodies elicited with the syngeneic anti-HLA-A2, 28 monoclonal antibody CR11-351. Mol Immunol 1993;30:287-300.
19. American Joint Committee on Cancer. Manual for staging of cancer. 4th ed. Philadelphia: Lippincott; 1992. p. 149-54.
20. Jemmerson R, Paterson Y. Mapping epitopes on a protein antigen by the proteolysis of antigen-antibody complexes. Science 1986;232:1001-4.
21. Burnens A, Demotz S, Corradin G, Binz H, Bosshard HR. Epitope mapping by chemical modification of free and antibody-bound protein antigen. Science 1987;235:780-3.
22. Hochleitner EO, Borchers C, Parker C, Bienstock RJ, Tomer KB. Characterization of a discontinuous epitope of the human immunodeficiency virus (HIV) core protein p24 by epitope excision and differential chemical modification followed by mass spectrometric peptide mapping analysis. Protein Sci 2000;9:487-96.
23. Mandell JG, Baerga-Ortiz A, Akashi S, Takio K, Komives EA. Solvent accessibility of the thrombin-thrombomodulin interface. J Mol Biol 2001;306:575-89.
24. Duffy MJ. CA15-3, and related mucins as circulating markers in breast cancer. Ann Clin Biochem 1999;36:579-86.
25. Duffy MJ. Biochemical markers in breast cancer: which ones are clinically useful? Clin Biochem 2001;34:347-52.
26. Cheung K, Graves CRL, Robertson JFR. Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 2000;26:91-102.
27. Hayes DF, Thor AD. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 2002;29:231-45.
28. Etzioni R, Urban N, Ramsey S. The case for early detection. Nat Rev Cancer 2003;3:243-52.
29. Duffy MJ. Predictive markers in breast and other cancers: a review. Clin Chem 2005;51:494-503.
30. Fuqua SA. The role of estrogen receptors in breast cancer metastasis. J Mammary Gland Biol Neoplasia 2001;6:407-17.
31. Bacus SS, Gudkov AV, Esteva FJ, Yarden Y. Expression of erbB receptors and their ligands in breast cancer: implications to biological behavior and therapeutic response. Breast Dis 1999;11:63-75.
32. Borresen-Dale AL. TP53 and breast cancer. Hum Mutat 2003;21:292-300.